Torl Bio Therapeutics announced it raised $158 Million in an initial filing from an offering of $158 Million

Company

Location

About

TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide. Through a strategic partnership with the Slamon Research Lab at UCLA, TORL has exclusive development and commercial rights to a large program of biologics-based drugs for promising, and novel cancer targets.